Completed PHASE3 INTERVENTIONAL 2-arm NCT01452776

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

A Phase 3, Randomized, Single-Blind, Multicenter Study to Evaluate the Safety of TAK-438 (10 and 20 mg Once-daily) in a 52-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE)

Sponsor: Takeda

Conditions Erosive Esophagitis

Interventions TAK-438

Updated 6 times since 2017 Last updated: Nov 2, 2013 Started: Sep 30, 2011 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01452776, this PHASE3 trial focuses on Erosive Esophagitis and remains completed. Sponsored by Takeda, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abiko-shi, Japan , Aki-gun, Japan , Amagasaki-shi, Japan , Annaka-shi, Japan , Chiyoda-ku, Japan , Chuo-ku, Japan , Fukuoka, Japan , Fuziidera-shi, Japan , Gifu, Japan , Hiroshima, Japan and 22 more locations